Domingo 19 de Noviembre 2017

Cynvenio Announces ClearID Total Insight, a New Comprehensive LiquidBiopsy Monitoring Program for Breast Cancer

  • New 12-month program consists of liquid biopsy for cancer mutation
    detection combined with quantification of immune system performance.
  • Goal of serial blood tests is to detect signs of recurrence in
    survivors or metastases in patients undergoing treatment.

WESTLAKE VILLAGE, Calif.–(BUSINESS WIRE)–Cynvenio Biosystems, Inc., a leader in personalized medicine technology
and cancer diagnostics, today announced the availability of ClearID®
Total Insight™ Breast Cancer, a liquid biopsy monitoring service for
patients in treatment and survivors in remission. This comprehensive
assessment of a patient’s biological health is designed to measure
immune health status and detect genetic mutations associated with cancer.

ClearID Total Insight is generally performed at regular intervals
throughout the year and consists of four ClearID DNA sequencing tests,
four NK-Score™ immune system assessment tests, and a BRCA 1 & 2
test provided by Cynvenio’s previously
announced
partner Color Genomics. The Color test identifies 30 of
the most common hereditary cancer genes.

A 12-month course of ClearID Total Insight monitoring costs less than a
single DNA sequencing test advertised by other genomic testing
companies. It is the first test of its kind conceived to support serial
genomic and immune system monitoring at a price point acceptable to
doctors, payors, and patients.

The information provided by the ClearID Total Insight monitoring program
can aid physicians in drug selection, risk assessment, treatment
stratification, evaluation of drug resistance, and selection of
monitoring frequency for their patients.

“Our new ClearID Total Insight monitoring service provides a proactive
way for patients to gain greater visibility into their health status
even before changes are detectable by imaging screens,” said Paul Song,
MD, Chief Medical Officer of Cynvenio. “This information can provide an
early warning system, complete with actionable information so patients
can work with their clinicians to address an issue before it becomes too
late to control or successfully treat the disease.”

Additional details are available at www.clearidmonitoring.com
and www.cynvenio.com.

About Cynvenio Biosystems, Inc.

Cynvenio’s liquid biopsy testing technology is leading the way to more
affordable and clinically actionable precision medicine strategies for
cancer patients. Among the company’s breakthroughs are its line of
ClearID® tests for greatly improved cancer detection and monitoring via
a patient-friendly blood draw, and a suite of proprietary, distributable
LiquidBiopsy® platforms and consumables for deployment in hospitals and
third-party diagnostic labs. Cynvenio is based in Westlake Village,
California (Los Angeles). For more information, please visit www.cynvenio.com,
www.clearidmonitoring.com
and www.liquidbiopsy.com.

LiquidBiopsy® and ClearID®, are registered trademarks, and ClearID
Breast Cancer Total Insight™ and NK-Score™ are trademarks, of Cynvenio
Biosystems, Inc.

Contacts

Bioscribe, Inc.
Nicole Litchfield, 1-415-793-6468
Nicole@bioscribe.com